Computer modeling shows how medications play a part in the Parkinson's experience

September 11, 2012

(Medical Xpress)—A University of Western Sydney researcher has developed a new computational model, which will improve our understanding of how Parkinson's disease (PD) medications affect the brain and cognition.

Dr Ahmed Moustafa, from the School of Social Sciences and Psychology and the MARCS Institute at UWS, says the primary symptoms of PD are thought to be the result of the insufficient formation and action of Dopamine.

"Dopamine is one of the neurotransmitters responsible for the way the human brain processes information," says Dr Moustafa.

"When Parkinson's patients experience symptoms of motor skill and cognitive dysfunction – such as muscle rigidity, tremors and a slowing of physical movement – it is believed that the disease has impaired the ability of their brains to produce this important chemical that led to the motor and ."

Along with colleagues Dr Mohammad Herzallah and Dr Mark Gluck from the Center for Neuroscience at Rutgers University, Dr Moustafa has devised a method of tracking the various affects of key Dopamine replacement therapies – such as Levodopa, and Ropinirole.

The 'computational model', to be published in the journal, provides a mechanistic account of several positive and negative effects of PD treatments.

Dr Moustafa says the key effect appears to lie within the activation of the D1 and D2 receptors.

"It appears that that the differential effects of dopamine medications are related to their binding to D1 and D2 receptors. It seems that these medications have variable effects on D1 receptors," says Dr Moustafa.

"By tracking how these different treatments affect different , we have been able to explain why some PD patients experience some very different ."

Dr Moustafa says treatments such as Levodopa, which produce added Dopamine by over stimulating the motor neurons, appear to have a higher affinity with these D1 receptors.

"Clinical research shows that the chronic administration of Levodopa can enhance ' cognition, but can also lead to a phenomenon known as Levodopa-induced Dyskinesia – a disorder which causes patients to have involuntary movements, most commonly in the upper body," he says.

"Other treatments, which do not activate the D1 receptors, do not have the same effects."

Dr Moustafa's will have wide-ranging implications for understanding the varied physical effects of Parkinson's disease, as well as the potential side-effects of Parkinson's medications.

"Clinical research also shows that a subset of Parkinson's patients develops what is known as impulse control disorders, which involve pathological gambling, hypersexuality, and binge eating," says Dr Moustafa.

"Basically, the brain's difficulty in processing information eventually impairs the patient's ability to learn to avoid negative outcomes – including gaining weight, and losing jobs, money and relationships.

"If the development of these impulse control disorders can be conclusively traced to the overstimulation of , it may be possible to understand why some Parkinson's patients develop impulse control disorders, and others do not – and then to regulate the medications that stimulate these specific receptors."

Related Stories

Recommended for you

Singing may be good medicine for Parkinson's patients

August 11, 2017
(HealthDay)—Singing? To benefit people with Parkinson's disease? It just may help, a researcher says.

Tracing the path of Parkinson's disease proteins

August 4, 2017
As neurodegenerative disorders such as Parkinson's and Alzheimer's disease progress, misfolded proteins clump together in neurons, recruiting normal proteins in the cell to also misfold and aggregate. Cells in which this ...

Diabetes drug shows potential as disease-modifying therapy for Parkinson's disease

August 3, 2017
A drug commonly used to treat diabetes may have disease-modifying potential to treat Parkinson's disease, a new UCL-led study suggests, paving the way for further research to define its efficacy and safety.

Two new studies offer insights into gastrointestinal dysfunction in Parkinson's patients

July 31, 2017
Constipation is one of the most common non-motor related complaints affecting Parkinson's disease (PD) patients. Two important studies from the same research group published in the Journal of Parkinson's Disease expand the ...

New drug may treat and limit progression of Parkinson's disease

July 31, 2017
Researchers at Binghamton University have developed a new drug that may limit the progression of Parkinson's disease while providing better symptom relief to potentially hundreds of thousands of people with the disease.

A new insight into Parkinson's disease protein

July 28, 2017
Abnormal clumps of certain proteins in the brain are a prominent feature of Parkinson's and other neurodegenerative diseases, but the role those same proteins might play in the normal brain has been unknown.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.